Last week, Autolomous was honored to support the Blood Centers of America Advanced Therapies Workshop. It was a privilege to stand alongside fellow sponsors Accellix , Thermo Fisher Scientific, Terumo Blood and Cell Technologies, Vitrafy Life Sciences, and LumaCyte as we work toward a more accessible future.

One staggering statistic shared by Sharon Anderson from the Alliance for Regenerative Medicine (ARM) continues to resonate: The chance of a patient receiving CAR-T therapy drops by 6.2% for every 10 miles they live from a treatment center. This demonstrates the significant barriers to patient access created by a centralised manufacturing model that has not yet evolved to meet a global need.

At Autolomous, we remain committed to digitising and streamlining the supply chain infrastructure that brings these advanced therapies closer to the patients who need them most.